Essential Cancer Research - on demand
Time-sensitive and reliable cancer news, research and analysis
covering clinical trials, drugs, treatments and cures worldwide
| For 24/7 unlimited access... | |
|---|---|
Subscribe now
|
or call us on: +43 (0)1 71 72 8 900 (Vienna) or on: +44 (0)20 7769 6707 (London) |
Pricing
Our pricing options are simple. There is one structure for corporates/professionals, and another special discounted structure for patients and their family.
1. Corporates/Professionals (Healthcare & Pharmaceutical)
For corporates/professionals the service costs €720/£720 a year per user. This works out at €60/£60 a month per user.
Corporates/professionals can subscribe to Cancer Stat by contacting us directly:
- by email: cancerstat@templetonapus.com
- by phone:
Vienna office, Austria, European Union: +43 (0)1 71 71 8 900
London office, United Kingdom: +44 (0)20 7769 6707
You have the option of taking a 3 week free trial to Cancer Stat before subscribing.
2. Patients/Family
Patients/family can subscribe to Cancer Stat at a special discounted rate by either of the following methods:
a. Making a single payment of £240 for a year's subscription via PayPal.
b. Paying £30 a month for an ongoing monthly subscription via PayPal.
Both options provide you with your own personal Cancer Stat account and can be found at: www.cancerstat.com/accounts/subscribe
You will have full access to all platform features and to the extensive email services. You can also request that drugs or treatments that are of special interest to you are added and tracked.
After signing up:
1. You will receive by email your login ID and password within 3 hours.
2. The email will include a weblink with a 10 minute video demo explaining how to most effectively use your Cancer Stat account.
3. You will be asked in the email if you have any specific information content requests.
Payments
1. Corporates/Professionals (Healthcare & Pharmaceutical)
Corporates/professionals will be invoiced.
2. Patients/Family
Patients/family can make secure payments using credit or debit cards via PayPal at: www.cancerstat.com/accounts/subscribe
Most viewed
- 1. CytoDyn to Hold Webcast on March 8 to Provide Overview of CD12 Trial Data and Regulatory Path Forward with the U.S., U.K., Canada, Philippines and Brazil
- 2. CytoDyn's Phase 3 Trial Demonstrates Safety, a 24% Reduction in Mortality and Faster Hospital Discharge for Mechanically Ventilated Critically Ill COVID-19 Patients Treated with Leronlimab
- 3. CytoDyn to File Accelerated Rolling Review with MHRA and Interim Order (IO) with Health Canada for COVID-19
- 4. STAT+: CytoDyn's wild weekend of data-mining study results ends in failure for its Covid treatment
- 5. Reirradiation by Nanoparticles and Hypofractionated Protontherapy of Relapses Tumors: Non-randomized Phase II Study.
- 6. Clinical Validation of Cervical Cancer Screening Methods
- 7. In France, there's no escape from Covid vaccine sceptics. What would Pasteur think?
- 8. Surgeons fear wave of lawsuits over delays to cancer treatment
- 9. Phase 1 cancer biotech Ikena Oncology files for a $100 million IPO
- 10. IPO for Oxford COVID-19 vaccine startup in peril
Last updated at 14:58 GMT
Hot News Makers
Health/Pharma Companies
-
25979.03
-
17950.48
-
17182.54
-
16025.98
-
15300.65
-
15014.65
-
13649.78
-
13222.78
-
12775.18
-
10070.70
Last updated at 14:10 GMT
© Copyright 2021 Templeton Apus. All rights reserved.
Made with 
and
in the EU & the UK
and
in the EU & the UK